Консенсус керівних настанов з клінічної практики ISPAD 2018 р. Розділ 9. Інсулінотерапія у дітей та підлітків з діабетом




Біографія автора

N. B. Zelinska

Переклад, підготовка до друку —
Зелінська Наталя Борисівна, 
д. мед. н., зав. відділу дитячої ендокринології УНПЦ ендокринної хірургії, трансплантації ендокринних органів і тканин МОЗ України


Danne T., Bangstad H.J., Deeb L et al. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2014;15 (suppl 20):115-134.

Bohn B., Karges B., Vogel C et al. 20 Years of Pediatric Benchmarking in Germany and Austria: Age-Dependent Analysis of Longitudinal Follow-Up in 63,967 Children and Adolescents with Type 1 Diabetes. PLoS One. 2016;ll (8). e0160971.

Mochizuki M., Kikuchi T., Urakami T et al. Improvement in glycemic control through changes in insulin regimens: findings from a Japanese cohort of children and adolescents with type 1 diabetes. Pediatr Diabetes. 2017;18 (6):435-442.

Johnsson S. Retinopathy and nephropathy in diabetes mellitus: comparison of the effects of two forms of treatment. Diabetes. 1960;9:1-8.

Fullerton B., Siebenhofer A., Jeitler K et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;6. CD012161.

Danne T., Deiss D., Hopfenmuller W., von Schutz W., Kordonouri O. Experience with insulin analogues in children. Horm Res. 2002. 57 (suppl l):46-53.

Mortensen H.B., Lindholm A., Olsen B.S., Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr. 2000;159:483-488.

Acerini C.L., Cheetham T.D., Edge J.A., Dunger DB. Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia. 2000;43:61-68.

Amiel S.A., Sherwin R.S., Simonson D.C., Lauritano A.A., Tamborlane WV. Impaired insulin action In puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med. 1986;315:215-219.

de Beaufort C.E., Houtzagers C.M., Bruining G.J. et al. Continuous subcutaneous insulin Infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow- up of a randomized, prospective trial. Diabet Med. 1989;6:766-771.

DCCT. Effect of Intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial. Diabetes control and complications trial research group. J Pediatr. 1994;125:177-188.

Jacobson A.M., Musen G., Ryan C.M. et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007;356:1842-1852.

Musen G., Jacobson A.M., Ryan C.M. et al. Impact of diabetes and Its treatment on cognitive function among adolescents who participated in the diabetes control and complications trial. Diabetes Care. 2008;31:1933-1938.

Mortensen H.B., Robertson K.J., Aanstoot H.J. et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabet Med. 1998;15:752-759.

Karges B., Kapellen T., Wagner V.M. et al. Glycated hemoglobin Ale as a risk factor for severe hypoglycemia in pediatric type 1 diabetes. Pediatr Diabetes. 2017;18 (l):51-58.

DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.

White N.H., Cleary P.A., Dahms W., Goldstein D., Malone J., Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001;139:804-812.

Battelino T., Conget I., Olsen B et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155-3162.

Elleri D., Allen J.M., Kumareswaran K et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care. 2013;36:838-844.

Phillip M., Battelino T., Atlas E et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med. 2013;368:824-833.

Weinzimer SA Steil G.M., Swan K.L., Dziura J., Kurtz N., Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31:934-939.

Howey D.C., Bowsher R.R., Bruneile R.L., Woodworth JR. (Lys (B28), Pro (B29))-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 1994 Mar;43(3):396-402.

Nosek L., Roggen K., Heinemann L., et a I. Insulin aspart has a shorter duration of action than human insulin over a wide dose-range. Diabetes Obes Metab. 2013;15 (l):77-83.

Bode B.W., McGill J.B., Lorber D.L. et al. Inhaled technosphere insulin compared with Injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015;38 (12):2266-2273.

Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14 (9):780-788.

Philotheou A., Arslanian S., Blatniczky L., Peterkova V., Souhami E., Danne T. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a basal-bolus insulin regimen in a 26-week trial In pediatric patients with type 1 diabetes. Diabetes Technol Ther. 2011;13:327-334.

Plank J., Wutte A., Brunner G et al. A direct comparison of Insulin aspart and insulin lispro In patients with type 1 diabetes. Diabetes Care. 2002;25:2053-2057.

Cemeroglu A.P., Kleis L., Wood A., Parkes C., Wood M.A., Davis AT. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 DM on multiple daily injections. Endocr Pract. 2013;19:614-619.

Heise T., Nosek L., Spitzer H et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9:746-753.

Kaiserman K., Jung H., Benabbad I., Karges B., Polak M., Rosilio M. 20 years of insulin lispro in pediatric type 1 diabetes: a review of available evidence. Pediatr Diabetes. 2017;18 (2):81-94.

Deeb L.C., Holcombe J.H., Brunelle R et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics. 2001;108:1175-1179.

Tubiana-Rufi N., Coutant R., Bloch J et al. Special management of insulin lispro in continuous subcutaneous insulin infusion In young diabetic children: a randomized cross-over study. Horn Res. 2004. 62:265-271.

Renner R., Pfutzner A., Trautmann M., Harzer O., Sauter K., Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSIl Study Group. Diabetes Care. 1999;22:784-788.

Rutledge K.S., Chase H.P., Klingensmith G.J., Walravens P.A., Slover R.H., Garg SK. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics. 1997;100:968-972.

Heller S.R., Colagiuri S., Vaaler S et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med. 2004;21:769-775.

Home P.D., Lindholm A., Riis A., European Insulin Aspart Study Group. Insulin aspart vs. human Insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial, (in process citation). Diabet Med. 2000;17:762-770.

Holcombe J.H., Zalani S., Arora V.K., Mast CJ. Comparison of Insulin lispro with regular human Insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002. 24:629-638.

Tupola S., Komulainen J., Jaaskelainen J., Sipila I. Post-prandial insulin lispro vs. human regular Insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med. 2001;18:654-658.

Ford-Adams M.E., Murphy N.P., Moore E.J. et al. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med. 2003;20:656-660.

Danne T., Aman J., Schober E et al. A comparison of postprandial and preprandial administration of Insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26:2359-2364.

Bode B.W., Johnson J.A., Hyveled L., Tamer S.C., Demissie M. Improved postprandial glycemic control with faster-acting Insulin Aspart In patients with type 1 diabetes using continuous subcutaneous Insulin Infusion. Diabetes Technol Ther. 2017 Jan;19 (l)):25-33.

Heise T., Pieber T.R., Danne T., Erichsen L., Haahr H. Pharmacodynamic characteristics of fast-acting insulin aspart In adults with type 1 diabetes. Clin Pharmacokinet. 2017. 56 (5):551-559.

Fath M., Danne T., Biester T., Erichsen L., Kordonouri O., Haahr H. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart In children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2017;18:903-910. https://doi. org/10.1111/pedi.l2506.

Russell-Jones D., Bode B.W., De Block C et al. Fast-acting Insulin aspart Improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1). Diabetes Care. 2017;40 (7):943-950.

Umpierrez G.E., Jones S., Smiley D et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care. 2009;32 (7):1164-1169.

Jehle P.M., Micheler C., Jehle D.R., Breitig D., Boehm BO. Inadequate suspension of neutral protamine Hagendorn (НПХ) insulin In pens (see comments). Lancet. 1999;354:1604-1607.

Lucid P, Porcellati F., Marinel IT Andreoli A., et a I. Pharmacokinetics and pharmacodynamics of НПХ insulin In type 1 diabetes: the Importance of appropriate resuspension before subcutaneous injection. Diabetes Care. 2015;38:2204-2210.

Lepore M., Pampanelli S., Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human Insulin analog glargine, НПХ insulin, and ultralente human Insulin and continuous subcutaneous infusion of Insulin lispro. Diabetes. 2000;49:2142-2148.

Chase H.P., Dixon B., Pearson J et al. Reduced hypoglycemic episodes and Improved glycemic control in children with type 1 diabetes using Insulin glargine and neutral protamine Hagedorn Insulin. J Pediatr. 2003;143:737-740.

Heise T., Nosek L., Ronn B.B. et al. Lower within-subject variability of insulin detemir In comparison to НПХ insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.

Danne T., Datz N., Endahl L et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than Insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes. 2008;9:554-560.

Hermansen K., Fontaine P., Kukolja K.K., Peterkova V., Leth G., Gall MA. Insulin analogues (Insulin detemir and Insulin aspart) versus traditional human insulins (НПХ insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia. 2004;47:622-629.

Schober E., Schoenle E., Van Dyk J., Wernicke-Panten K. Comparative trial between Insulin glargine and НПХ Insulin in children and adolescents with type 1 diabetes. Diabetes Care. 2001;24:2005-2006.

Debrah K., Sherwin R.S., Murphy J., Kerr D. Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetes. Lancet. 1996;347:19-24.

Porcellati F., Rossetti P., Pampanelli S et al. Better long-term glycae- mic control with the basal insulin glargine as compared with НПХ in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med. 2004;21:1213-1220.

NICE (National Institute of Clinical Excellence). Diabetes (type 1 and type 2) In children and young people: diagnosis and management. NICE guideline (NG18) https://www.nice.org.uk/guidance/ngl8. accessed July 21, 2018.

Hathout E.H., Fujishige L., Geach J., Ischandar M., Maruo S., Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther. 2003;5:801-806.

Alemzadeh R., Berhe T., Wyatt DT. Flexible insulin therapy with glargine insulin Improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics. 2005;115:1320-1324.

Mohn A., Strang S., Wernicke-Panten K., Lang A.M., Edge J.A., Dunger DB. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care. 2000;23:557-559.

Robertson K.J., Schoenle E., Gucev Z., Mordhorst L., Gall M.A., Ludvigsson J. Insulin detemir compared with НПХ insulin In children and adolescents with type 1 diabetes. Diabet Med. 2007;24:27-34.

Danne T., Lupke K., Waite K., Von Schuetz W., Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003;26:3087-3092.

Vague P., Selam J.L., Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than НПХ insulin In patients with type 1 diabetes on a basal-bolus regimen with premeal Insulin aspart. Diabetes Care. 2003;26:590-596.

Dixon B., Peter Chase H., Burdick J et al. Use of Insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes. 2005;6:150-154.

Thisted H., Johnsen S.P., Rungby J. An update on the long-acting insulin analogue glargine. Basic Clir) Pharmacol Toxicol. 2006. 99:1-11.

Paivarinta M.,Tapanainen P., Veijola R. Basal insulin switch from НПХ to glargine In children and adolescents with type 1 diabetes. Pediatr Diabetes. 2008;9:83-90.

Danne T., Philotheou A., Goldman D et al. A randomized trial comparing the rate of hypoglycemia-assessed using continuous glucose monitoring-in 125 preschool children with type 1 diabetes treated with insulin glargine or НПХ insulin (the PRESCHOOL study). Pediatr Diabetes. 2013;14:593-601.

Hamann A., Matthaei S., Rosak C., Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26:1738-1744.

Heise T., Bott S., Rave K., Dressier A., Rosskamp R., Heinemann L. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with type 1 diabetes. Diabet Med. 2002;19:490-495.

Ratner R.E., Hirsch I.B., Neifing J.L., Garg S.K., Mecca Т.Е., Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U. S. Study Group of Insulin Glargine in type 1 diabetes. Diabetes Care. 2000;23:639-643.

Steinstraesser A., Schmidt R., Bergmann K., Dahmen R., Becker RHA Investigational new insulin glargine 300 U/mL has the same metabolism as glargine 100 U/mL. Diabetes Obes Metab. 2014;16:873-876.

Danne T., Becker R.H., Ping L., Philotheou A. Insulin glargine metabolite 21 (A)-Gly-human insulin (Ml) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Pediatr Diabetes. 2015;16:299-304.

Gerstein H.C., Bosch J., Dagenais G.R. et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.

Home P.D., Bergenstal R.M., Bolli G.B. et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38:2217-2225.

Home P.H., Bergenstal R.M., Bolli G.B. et al. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4). Diabetes Obes Metab. 2017;43:351-358.

Matsuhisa M., Koyama M., Cheng X et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP1). Diabetes Obes Metab. 2016;18:375-383.

Bergenstal R.M., Bailey T.S., Rodbard D et al. Comparison of insulin glargine 300 units/mL and 100 units/mL in adults with type 1 diabetes: continuous glucose monitoring profiles and variability using morning or evening injections. Diabetes Care. 2017;40:554-560.

Plank J., Bodenlenz M., Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-1112.

NImrl R., Lebenthal Y., Shalitin S., Benzaquen H., Demol S., Phillip M. Metabolic control by Insulin detemir in basal-bolus therapy: treat-to-target study In children and adolescents with type 1 diabetes. Pediatr Diabetes. 2013;14 (3):196-202.

Abali S., Turan S., Atay Z., Guran T., Haliloglu B., Bereket A. Higher Insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus. Pediatr Diabetes. 2015;16 (5):361-366.

Russell-Jones D., Danne T., Hermansen K et al. Weight-sparing effect of Insulin detemir: a consequence of central nervous system-mediated reduced energy Intake?. Diabetes Obes Metab. 2015;17 (10):919-927.

Thalange N., Bereket A., Larsen J., Hiort L.C., Peterkova V. Insulin analogues in children with type 1 diabetes: a 52-week randomized clinical trial. Diabet Med. 2013;30 (2):216-225.

Carlsson A., Forsander G., Ludvigsson J., Larsen S., Ortqvist E., Group SP-YS. A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes. Pediatr Diabetes. 2013;14:358-365.

Mathieu C., Hollander P., MIranda-Palma B et al. Bain SC; NN1250-3770 (BEGIN: flex Tl) trial Investigators. Efficacy and safety of insulin degludec In a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: flex Tl): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98 (3):1154-1162.

Blester T., Blaesig S., Remus K., et a I. Insulin degludec’s ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2014;15:27-33.

Thalange N., Deeb L., lotova V. et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2015;16:164-176.

Kurtzhals P., Schaffer L., Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of Insulin analogs designed for clinical use. Diabetes. 2000;49:999-1005.

Hemkens L.G., Grouven U., Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or Insulin analogues: a cohort study. Diabetologia. 2009;52 (9):1732-1744.

Colhoun H.M., SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52 (9):1755-1765.

Jonasson J.M., Ljung R., Talback M., Haglund B., Gudbjornsddttir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009;52 (9):1745-1754.

Currie C.J., Poole C.D., Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52 (9):1766-1777.

European Medicines Agency. Outcome of review of new safety data on insulin glargine. http://www.ema.europa.eu/docs/en_GB/document_ library/Medicine_QA/2013/05/WC500143823.pdf. accessed July 22, 2018.

Thalange N., Bereket A., Jensen L.B., Hiort L.C., Peterkova V. Development of insulin Detemir/insulin aspart cross-reacting antibodies following treatment with insulin Detemir: 104-week study in children and adolescents with type 1 diabetes aged 2-16 years. Diabetes Ther 2016. 7 (4):713-724.

Mortensen H., Kocova M., Teng L.Y., Keiding J., Bruckner I., Philotheou A. Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. Pediatr Diabetes. 2006;7:4-10.

Davies M., Dahl D., Heise T., Kiljanski J., Mathieu C. Introduction of biosimilar insulins in Europe. Diabet Med. 2017;34 (10):1340-1353.

Stickelmeyer M.P., Graf C.J., Frank B.H., Ballard R.L., Storms SM. Stability of U-10 and U-50 dilutions of insulin lispro. Diabetes Technol Ther. 2000;2:61-66.

Jorgensen D., Solbeck H. Dilution of insulin aspart with НПХ medium for small dose use in continuous subcutaneous insulin infusion does not affect in vitro stability. Diabetes. 2005;54 (suppl 1):A102 (abstract).

Datz N., von Schutz W., Nestoris C et al. Increase of insulin requirements after changing from U40 to U100 insulin in children and adolescents with type 1 diabetes without effect on the metabolic status. Pediatr Diabetes. 2008;9:59 (abstract).

Grajower M.M., Fraser C.G., Holcombe J.H., etal. How long should insulin be used once a vial is started?. Diabetes Care. 2003;26:2665-2666. discussion 266-9.

Ogle G.D., Abdullah M., Mason D., Januszewski A.S., Besangon S. Insulin storage in hot climates without refrigeration: temperature reduction efficacy of clay pots and other techniques. Diabet Med. 2016;33 (11):1544-1553.

Schuler G., Pelz K., Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diabetes Res Clin Pract. 1992. 16:209-212.

McCarthy J.A., Covarrubias B., Sink P. Is the traditional alcohol wipe necessary before an insulin injection? Dogma disputed. Diabetes Care. 1993;16:402.

Loeb J.A., Herold К.С., Barton K.P., Robinson L.E., Jaspan JB. Systematic approach to diagnosis and management of biphasic insulin allergy with local anti-inflammatory agents. Diabetes Care. 1989;12:421-423.

Kordonouri O., Lauterborn R., Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care. 2002;25:634.

Holstein A., Stege H., Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Saf. 2010. 9:225-231.

Forsander G.A., Malmodin О.С., Kordonuri O., Ludvigsson J., Klingensmith G., Beaufort CD. An ISPAD survey insulin-induced lipoatrophy. Pediatr Diabetes. 2013;14:1.

Schnell K., Biester T., Tsioli C., Datz N., Danne T., Kordonuri O. Lipoatrophy in a lagre pediatric diabetes outpatient service. Pediatr Diabetes. 2013;14:20.

Chantelau E., Lee D.M., Hemmann D.M., Zipfel U., Echterhoff S. What makes insulin injections painful?. BMJ. 1991;303:26-27.

Hanas R., Adolfsson P., Elfvin-Akesson K et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr. 2002;140:315-320.

Arendt-Nielsen L., Egekvist H., Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res 2006. 23:37-43.

Ginsberg B.H., Parkes J.L., Sparacino C. The kinetics of insulin administration by insulin pens. Horm Metab Res. 1994. 26:584-587.

Lauritzen T. Pharmacokinetic and clinical aspects of intensified subcutaneous insulin therapy. Dan Med Bull. 1985. 32:104-118.

Sindelka G., Heinemann L., Berger M., Frenck W., Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Dia- betologia. 1994. 37:377-380.

Young R.J., Hannan W.J., Frier B.M., Steel J.M., Duncan LJ. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care. 1984;7:479-480.

Johansson U.B., Amsberg S., Hannerz L et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care. 2005;28:2025-2027.

Bantle J.P., Neal L., Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care. 1993;16:1592-1597.

Frid A., Gunnarsson R., Guntner P., Linde B. Effects of accidental intramuscular injection on insulin absorption in IDDM. Diabetes Care. 1988;11:41-45.

Frid A., Ostman J., Linde B. Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care. 1990;13:473-477.

Frid A. Injection and absorption of insulin (PhD thesis). Stockholm, Sweden: Faculty of Medicine, Karolinska Institute; 1992.

Mudaliar S.R., Lindberg F.A., Joyce M et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501-1506.

ter Braak E.W., Woodworth J.R., Bianchi R et al. Injection site effects on the pharmacokinetics and glucodynamics of Insulin lispro and regular insulin. Diabetes Care. 1996;19:1437-1440.

Rave K., Heise T., Weyer C et al. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects. Diabet Med. 1998;15:747-751.

Owens D.R., Coates P.A., Luzio S.D., Tinbergen J.P., Kurzhals R. Pharmacokinetics of 1251-labeled insulin glargine (HOE 901) in healthy men: comparison with НПХ insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23:813-819.

Peter R., Luzio S.D., Dunseath G et al. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2005;28:560-565.

Karges B., Boehm B.O., Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med. 2005;22:1444-1445.

Morrow L., Muchmore D.B., Hompesch M., Ludington E.A., Vaughn DE. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care. 2013;36:273-275.

Cengiz E., Weinzimer S.A., Sherr J.L. et al. Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming. Diabetes Tecbnol Tber. 2014. 16:20-25.

Frid A.H., Kreugel G., Grassi G et al. New insulin delivery recommendations. Mayo Clin Proc. 2016. 91 (9):1231-1255.

Hofman P.L., Lawton S.A., Peart J.M. et al. An angled insertion technique using 6-mm needles markedly reduces the risk of Intramuscular injections in children and adolescents. Diabet Med. 2007;24:1400-1405.

Birkebaek N.H., Johansen A., Solvig J. Cutis/subcutis thickness at Insulin injection sites and localization of simulated Insulin boluses In children with type 1 diabetes mellitus: need for individualization of Injection technique?. Diabet Med. 1998;15:965-971.

Smith C.P., Sargent M.A., Wilson B.P., Price DA. Subcutaneous or intramuscular insulin Injections. Arch Dis Child. 1991;66:879-882.

Hanas S.R., Ludvigsson J. Metabolic control is not altered when using indwelling catheters for insulin Injections. Diabetes Care. 1994;17:716-718.

Burdick P., Cooper S., Horner B., Cobry E., McFann K., Chase HP. Use of a subcutaneous Injection port to improve glycemic control in children with type 1 diabetes. Pediatr Diabetes. 2009;10:116-119.

Cengiz E., Tamborlane W.V., Martin-Fredericksen M., Dziura J., Weinzimer SA. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine Insulin: results of glucose clamp studies In youth with type 1 diabetes. Diabetes Care. 2010;33:1009-1012.

Cengiz E., Swan K.L., Tamborlane W.V., Sherr J.L., Martin M., Weinzimer SA. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care. 2012;35:690-692.

Hanas S.R., Carlsson S., Frid A., Ludvigsson J. Unchanged insulin absorption after 4 days’ use of subcutaneous indwelling catheters for insulin injections. Diabetes Care. 1997;20:487-490.

Hanas R., Ludvigsson J. Side effects and Indwelling times of subcutaneous catheters for insulin injections: a new device for injecting insulin with a minimum of pain in the treatment of Insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1990. 10:73-83.

Engwerda E.E., Tack C.J., de Galan BEJ. Pharmacokinetic and Pharmacodynamic variability of insulin when administered by jet injection. J Diabetes Sci Technol. 2017;ll (5):947-952.

Chiasson J.L., Ducros F., Poliquin-Hamet M., Lopez D., Lecavalier L., Hamet P. Continuous subcutaneous insulin infusion (Mill-Hill infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care. 1984;7:331-337.

Houtzagers C.M., Visser A.P., Berntzen P.A., Heine R.J., van der Veen EA. The Medi-Jector II: efficacy and acceptability in insulin-dependent diabetic patients with and without needle phobia. Diabet Med. 1988;5:135-138.

Engwerda E.E., Abbink E.J., Tack C.J., de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care. 2011;34:1804-1808.

Litton J., Rice A., Friedman N., Oden J., Lee M.M., Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr. 2002;141:490-495.

Berghaeuser M.A., Kapellen T., Heidtmann B., Haberland H., Klinkert C., Holl RW. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes. 2008;9:590-595.

Skogsberg L., Fors H., Hanas R., Chaplin J.E., Lindman E., Skogsberg J. Improved treatment satisfaction but no difference In metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes. 2008;9:472-479.

Bolli G.B., Kerr D., Thomas R et al. Comparison of a multiple daily Insulin injection regimen (basal once-daily glargine plus mealtime lis- pro) and continuous subcutaneous insulin Infusion (lispro) In type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care. 2009;32:1170-1176.

Colquitt J., Royle P., Waugh N. Are analogue insulins better than soluble In continuous subcutaneous insulin Infusion? Results of a meta-analysis. Diabet Med. 2003;20:863-866.

Sulmont V., Souchon P.F., Gouillard-Darnaud C et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin Infusion as a first line treatment?. J Pediatr. 2010;157:103-107.

Danne T., Battelino T., Jarosz-Chobot P et al. Establishing glycaemic control with continuous subcutaneous Insulin infusion In children and adolescents with type 1 diabetes: experience of the PedPump study in 17 countries. Diabetologia. 2008;51:1594-1601.

Phillip M., Battelino T., Rodriguez H., Danne T., Kaufman F. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of diabetes. Diabetes Care. 2007;30:1653-1662.

Pankowska E., Blazik M., Dziechciarz P., Szypowska A., Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes. 2009;10:52-58.

DiMeglio L.A., Pottorff T.M., Boyd S.R., France L., Fineberg N., Eugster EA. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr. 2004;145:380-384.

Wilson D.M., Buckingham B.A., Kunselman E.L., Sullivan M.M., Paguntalan H.U., Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005;28:15-19.

Sullivan-Bolyai S., Knafl K., Tamborlane W., Grey M. Parents’ reflections on managing their children’s diabetes with insulin pumps. J Nurs Scholarsh. 2004;36:316-323.

Blackman S.M., Raghinaru D., Adi S et al. Insulin pump use in young children in the T1D exchange clinic registry is associated with lower hemoglobin Ale levels than injection therapy. Pediatr Diabetes. 2014;15:564-572.

Kapellen T.M., Heidtmann B., Bachmann J., Ziegler R., Grabert M., Holl RW. Indications for insulin pump therapy in different age groups: an analysis of 1,567 children and adolescents. Diabet Med. 2007;24:836-842.

Sundberg F., Barnard K., Cato A., de Beaufort C., DiMeglio L.A., Dooley G., Hershey T., Hitchcock J., Jain V., Weissberg-Benchell J., Rami-Mer- har B, Smart C.E., Hanas R. ISPAD Guidelines. Managing diabetes in preschool children. Pediatr Diabetes. 2017;18:499-517.

Blackett PR. Insulin pump treatment for recurrent ketoacidosis in adolescence (letter). Diabetes Care. 1995;18:881-882.

Steindel B.S., Roe T.R., Costin G., Carlson M., Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract. 1995;27:199-204.

NICE (National Institute of Clinical Excellence). Clinical and cost effectiveness of continuous subcutaneous insulin infusion for diabetes. Technology Appraisal No 57. 2003. http://www.nice.org. uk/guidance/TA57.

Nahata L. Insulin therapy In pediatric patients with type I diabetes: continuous subcutaneous insulin Infusion versus multiple daily injections. Clin Pediatr (Pbila). 2006;45:503-508.

Kordonouri O., Pankowska E., Rami B et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia. 2010;53:2487-2495.

Apablaza P., Soto N., Codner E. From Insulin pump and continuous glucose monitoring to the artificial pancreas. Rev Med Cbil. 2017. 145:630-640.

Danne T., von Schutz W., Lange K., Nestoris C., Datz N., Kordonouri O. Current practice of insulin pump therapy in children and adolescents — the Hannover recipe. Pediatr Diabetes. 2006;7 (suppl 4):25-31.

Enander R., Gundevall C., Stromgren A., Chaplin J., Hanas R. Carbohydrate counting with a bolus calculator Improves post-prandial blood glucose levels in children and adolescents with type 1 diabetes using insulin pumps. Pediatr Diabetes. 2012;13:545-551.

Zisser H., Robinson L., Bevier W et al. Bolus calculator: a review of four «smart» insulin pumps. Diabetes Technol Ther. 2008;10:441-444.

Hanas R., Lundqvist K., WIndell L. Blood glucose and beta-hydroxybutyrate responses when the Insulin pump is stopped in children and adolescents. Pediatr Diabetes. 2006;7 (suppl 5):35 (abstract).

Ahern JAH, Boland E.A., Doane R et al. Insulin pump therapy In pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes. 2002;3:10-15.

Sulli N., Shashaj B. Long-term benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes: a 4-year follow-up. Diabet Med. 2006;23:900-906.

Johnson S.R., Cooper M.N., Jones T.W., Davis EA. Long-term outcome of insulin pump therapy In children with type 1 diabetes assessed In a large population-based case-control study. Diabetologia. 2013;56:2392-2400.

Karges B., Schwandt A., Heidtmann B et al. Association of Insulin Pump Therapy vs Insulin Injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes. JAMA. 2017;318 (14):1358-1366.

Hanas R., Ludvigsson J. Hypoglycemia and ketoacidosis with Insulin pump therapy in children and adolescents. Pediatr Diabetes. 2006;7- (suppl 4):32-38.

Margeirsdottir H.D., Larsen J.R., Kummernes S.J., Brunborg C., Dahl-Jorgensen K. The establishment of a new national network leads to quality improvement in childhood diabetes: implementation of the ISPAD guidelines. Pediatr Diabetes. 2010;ll (2):88-95.

Hanas R., Lindgren F., Lindblad B. A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use. Pediatr Diabetes. 2009;10:33-37.

Urakami T., Habu M., Suzuki J. DKA and severe hypoglycemia in management of type 1 diabetes during 2003-2013. Pediatr Int. 2014. 56:940.

Deiss D., Adolfsson P., Alkemade-van Zomeren M et al. Insulin infusion set use: European perspectives and recommendations. Diabetes Technol Ther. 2016;18 (9):517-524.

Evert A.B., Bode B.W., Buckingham B.A. et al. Improving patient experience with insulin infusion sets: practical guidelines and future directions. Diabetes Educ. 2016;42 (4):470-484.

Cescon M., DeSalvo D.J., Ly T.T. et al. Early detection of infusion set failure during insulin pump therapy in type 1 diabetes. Diabetes Sci Technol. 2016;10 (6):1268-1276.

Zisser H. Quantifying the impact of a short-interval interruption of insulin-pump infusion sets on glycemic excursions. Diabetes Care. 2008;31:238-239.

Baysal N., Cameron F., Buckingham B.A. et al. In Home Closed-Loop Study Group (IHCL)A novel method to detect pressure-induced sensor attenuations (PISA) in an artificial pancreas. J Diabetes Sci Technol. 2014;8 (6):1091-1096.

Liu D., Moberg E., Wredling R., Lins P.E., Adamson U. Insulin absorption is faster when keeping the infusion site in use for three days during continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 1991;12:19-24.

Bode B., Weinstein R., Bell D et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care. 2002;25:439-444.

Van Bon ACT Bode BWT Sert-Langeron CT DeVries JHT Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther. 2011;13:607-614.

Wood J.R., Moreland E.C., Volkening L.K., Svoren B.M., Butler D.A., Laffel LM. Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care. 2006;29:2355-2360.

Weinzimer S., Xing D., Tansey M et al. Freestyle navigator continuous glucose monitoring system use in children with type 1 diabetes using glargine-based multiple daily dose regimens: results of a pilot trial Diabetes Research in Children Network (DirecNet) study group. Diabetes Care. 2008;31:525-527.

Peyrot M., Rubin R.R., STAR 3 STUDY Group. Treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial. Diabet Med. 2013;30:464-467.

Slover R.H., Welsh J.B., Criego A et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes. 2012;13:6-11.

Buse J.B., Kudva Y.C., Battelino T., Davis S.N., Shin J., Welsh JB. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther. 2012;14:644-647.

Buckingham B., Cobry E., Clinton P et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther. 2009;11:93-97.

Biester T., Kordonouri O., Holder M et al. «Let the algorithm do the work»: reduction of hypoglycemia using sensor-augmented pump therapy with predictive insulin suspension (SmartGuard) in pediatric type 1 diabetes patients. Diabetes Technol Ther. 2017;19 (3):173-182.

Abraham M.B., Nicholas J.A., Smith G.J. et al. Reduction in hypoglycemia with the predictive low-glucose management system: a long-term randomized controlled trial in adolescents with type 1 diabetes. Diabetes Care. 2018;41:303-310.

Bergenstal R.M., Garg S., Weinzimer S.A. et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316 (13):1407-1408.

Garg S.K., Weinzimer S.A., Tamborlane W.V. et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19 (3):155-163.

Stone J.Y., Haviland N., Bailey TS. Review of a commercially available hybrid closed-loop insulin-delivery system in the treatment of type 1 diabetes. Ther Deliv. 2018. 9 (2):77-87.

Messer L.H., Forlenza G.P., Sherr J.L. et al. Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the MiniMed 670G System. Diabetes Care. 2018;41 (4):789-796.

Wysocki T., Harris M.A., Buckloh L.M. et al. Self-care autonomy and outcomes of intensive therapy or usual care in youth with type 1 diabetes. J Pediatr. Psychol. 2006. 31 (10):1036-1045.

Halberg I., Jacobsen L., Dahl U. A study on self-mixing insulin aspart with НПХ insulin in the syringe before injection. Diabetes. 1999;48- (suppl 1):: Abstract):448.

Joseph S.E., Korzon-Burakowska A., Woodworth J.R. et al. The action profile of lispro is not blunted by mixing in the syringe with НПХ insulin. Diabetes Care. 1998;21:2098-2102.

Kaplan W., Rodriguez L.M., Smith O.E., Haymond M.W., Heptulla RA. Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care. 2004;27:2739-27A0.

Fiallo-Scharer R., Horner B., McFann K., Walravens P., Chase HP. Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus. J Pediatr. 2006;148:481-484.

Nguyen T.M., Renukuntla V.S., Heptulla RA. Mixing insulin aspart with detemir does not affect glucose excursion In children with type 1 diabetes. Diabetes Care. 2010;33 (8):1750-1752.

Pankowska E., Blazik M., Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther. 2012;14:16-22.

Neu A., Lange K., Barrett T., et a I. Classifying insulin regimens-difficulties and proposal for comprehensive new definitions. Pediatr Diabetes. 2015;16 (6):402-406.

Cobry E., McFann K., Messer L et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12:173-177.

Luijf Y.M., van Bon A.C., Hoekstra J.B., Devries JH. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010;33:2152-2155.

Sackey A.H., Jefferson IG. Interval between Insulin injection and breakfast in diabetes. Arcb Dis Cbi/d. 1994. 71 (3):248-250.

Weinzimer S., Xing D., Tansey M et al. Prolonged use of continuous glucose monitors In children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily Injection therapy. Pediatr Diabetes. 2009;10:91-96.

Edge J., Acerini C., Campbell F et al. An alternative sensor-based method for glucose monitoring In children and young people with diabetes. Arcb Dis Child. 2017. 102 (6):543-549.

Trout K.K., RIckels M.R., Schutta M.H. et al. Menstrual cycle effects on insulin sensitivity In women with type 1 diabetes: a pilot study. Diabetes Technol Ther. 2007;9 (2):176-182.

Codner E., Merino P.M., Tena-Sempere M. Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum Reprod Update. 2012. 18:568-585.

Chowdhury S. Puberty and type 1 diabetes. Indian J Endocrinol Metab. 2015;19 (suppl 1):S51—S54.

Tan C.Y., Wilson D.M., Buckingham B. Initiation of Insulin glargine In children and adolescents with type 1 diabetes. Pediatr Diabetes. 2004;5:80-86.

O’Connell M.A., Gilbertson H.R., Donath S.M., Cameron FJ. Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using Insulin pump therapy: impact of glycemic Index and prandial bolus type. Diabetes Care. 2008;31:1491-1495.

Paterson M.A., Smart C.E., Lopez P.E. et al. Influence of dietary protein on postprandial blood glucose levels in individuals with type 1 diabetes mellitus using intensive insulin therapy. Diabet Med. 2016;33 (5):592-598.

Davidson P.C., Hebblewhite H.R., Steed R.D., Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract. 2008;14:1095-1101.

Conrad S.C., McGrath M.T., Gitelman SE. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr. 2002;140:235-240.

Nicolajsen T., Samuelsson A., Hanas R. Insulin doses before and one year after pump start: children have a reversed Dawn phenomenon. J Diabetes Sci Technol. 2012;6:589-594.

Szypowska A., Lipka M., Blazik M., Groele L., Pankowska E. Insulin requirement in preschoolers treated with insulin pumps at the onset of type 1 diabetes mellitus. Acta Paediatr. 2009;98:527-530.

Ludvigsson J., Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111:933-938.






Стандарти та консенсуси